This clinical trial is focused on studying treatments for gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, which are types of cancer that affect the stomach and the area where the stomach meets the esophagus. The study is testing a combination of treatments to see how effective they are in improving outcomes for patients with these cancers. The main treatment being tested is pembrolizumab, also known by its code name MK-3475, which is a type of medication that helps the immune system fight cancer. Pembrolizumab is being combined with different chemotherapy drugs, including cisplatin, capecitabine, 5-fluorouracil, docetaxel, oxaliplatin, and calcium folinate (also known as leucovorin calcium). A placebo, which looks like the real treatment but does not contain the active drug, is also used for comparison.
The purpose of the study is to evaluate how well these treatments work in preventing the cancer from coming back or spreading, and to assess the overall survival of patients. The study will also look at the safety and side effects of the treatments. Participants will receive the treatments before and after surgery to remove the cancer. The study will follow participants over a period of time to monitor their health and the effectiveness of the treatments.
Throughout the study, participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study aims to provide valuable information on the best treatment options for patients with gastric and GEJ adenocarcinoma, helping to improve future care and outcomes for individuals with these types of cancer.
Belgium 
Estonia 
France 
Germany 
Italy 
Latvia 
Lithuania 
Poland 